

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)



(10) International Publication Number
WO 2022/109078 A1

(51) International Patent Classification:

A61K 47/54 (2017.01) A61K 38/28 (2006.01)
C07F 5/02 (2006.01) A61P 3/10 (2006.01)
C07K 14/62 (2006.01)

(21) International Application Number:

PCT/US2021/059802

(22) International Filing Date:

18 November 2021 (18.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/116,050 19 November 2020 (19.11.2020) US
63/122,338 07 December 2020 (07.12.2020) US
63/210,968 15 June 2021 (15.06.2021) US
63/249,868 29 September 2021 (29.09.2021) US

(71) Applicant: **PROTOMER TECHNOLOGIES INC.**
[US/US]; Lilly Corporation Center, Indianapolis, Indiana
46285 (US).

(72) Inventors: **SPENCER, Ryan, Kelly**; c/o Protomer Technologies INC., Lilly Corporation Center, Indianapolis, Indiana 46285 (US). **CHEN, Diao**; c/o Protomer Technologies INC., Lilly Corporation Center, Indianapolis, Indiana 46285 (US). **MALI, Sachitanand**; c/o Protomer Technologies INC., Lilly Corporation Center, Indianapolis, Indiana 46285 (US). **HALE, Jack, Joseph**; c/o Protomer Technologies INC., Lilly Corporation Center, Indianapolis, Indiana 46285 (US). **LIANG, Jingxin**; c/o Protomer Technologies INC., Lilly Corporation Center, Indianapolis, Indiana 46285 (US). **SHAKER, Mirna, Ekram, Anwar**; c/o Protomer Technologies INC., Lilly Corporation Center, Indianapolis, Indiana 46285 (US). **MAHDAVI, Alborz**; c/o Protomer Technologies INC., Lilly Corporation Center, Indianapolis, Indiana 46285 (US).

(74) Agent: **OCHIANA, Stefan, O.**; Finnegan, Henderson, Farabow, Garrett, & Dunner L.L.P., 901 New York Avenue, NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS

(57) Abstract: The present disclosure relates to novel compounds that include one or more aromatic boron-containing groups. The present disclosure further relates to pharmaceutical compositions containing such compounds, and their use in prevention and treatment of disorders, such as hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, metabolic syndrome X, dyslipidemia, diabetes during pregnancy, pre-diabetes, Alzheimer's disease, MODY 1, MODY 2 or MODY 3 diabetes, mood disorders, and psychiatric disorders.

WO 2022/109078 A1